Comprehensive medication guide to Zoryve including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$150 copay with commercial insurance and the ZORYVE Direct Savings Card; most plans require prior authorization and place Zoryve on specialty or Tier 3; Medicare Part D coverage varies by plan.
Estimated Cash Pricing
$950–$1,145 retail for a 60-gram tube (brand only, no generic available); GoodRx coupons may reduce the price to approximately $932 per tube at select pharmacies.
Medfinder Findability Score
60/100
On this page
Zoryve (roflumilast) is a prescription topical medication manufactured by Arcutis Biotherapeutics, Inc. It is available as a cream (in 0.05%, 0.15%, and 0.3% strengths) and as a foam (0.3%), and is FDA-approved to treat three common inflammatory skin conditions: plaque psoriasis, atopic dermatitis (eczema), and seborrheic dermatitis.
First approved by the FDA in July 2022, Zoryve represents a new class of topical dermatology treatment — a phosphodiesterase-4 (PDE4) inhibitor — that is neither a corticosteroid nor an immunosuppressant. It can be used once daily, long-term, on any part of the body, including sensitive areas like the face, skin folds, and genitals where steroid use is limited.
As of 2026, Zoryve is the #1 prescribed branded topical across eczema, seborrheic dermatitis, and plaque psoriasis combined. There is no generic equivalent available, which means cost and prior authorization remain significant access challenges for many patients.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Zoryve's active ingredient, roflumilast, works by selectively inhibiting the enzyme phosphodiesterase-4 (PDE4) inside skin cells. PDE4 normally breaks down a molecule called cyclic AMP (cAMP), which acts as a natural anti-inflammatory signal inside cells.
By blocking PDE4, roflumilast prevents the breakdown of cAMP, allowing it to accumulate. Higher cAMP levels suppress the production of key pro-inflammatory cytokines — including interleukin-17 (IL-17), interleukin-23 (IL-23), interferon-gamma, and tumor necrosis factor alpha (TNF-α) — that drive the inflammation underlying psoriasis, atopic dermatitis, and seborrheic dermatitis.
Unlike topical corticosteroids, Zoryve's mechanism does not involve steroid receptors, which means it does not cause skin thinning, adrenal suppression, or the other steroid-related side effects that limit long-term use. Itch relief can begin within 24 hours of the first application; visible skin improvement typically begins within 2–4 weeks.
0.3% — cream
Plaque psoriasis in adults and children 2 years and older. Applied once daily to affected areas.
0.15% — cream
Mild to moderate atopic dermatitis in adults and children 6 years and older. Applied once daily.
0.05% — cream
Mild to moderate atopic dermatitis in pediatric patients ages 2 to 5 years. Applied once daily.
0.3% — foam
Seborrheic dermatitis in patients 9 years and older; plaque psoriasis of scalp and body in patients 12 years and older. Applied once daily to dry skin.
Zoryve is not listed on the FDA's official drug shortage database as of 2026. Arcutis Biotherapeutics continues to manufacture all formulations without reported supply disruptions. However, access remains challenging for many patients for several reasons:
Limited retail stocking: Because Zoryve is an expensive specialty drug, many community retail pharmacies don't carry it routinely.
Prior authorization requirements: Most insurance plans require PA before covering Zoryve, adding days to weeks of delay.
High cash price: At $950–$1,145 per tube without insurance, many patients cannot afford it without the manufacturer savings programs.
Specialty pharmacies (CVS Specialty, Walgreens Specialty, Accredo, Optum) are the most reliable sources for Zoryve. If you're having trouble locating it, medfinder calls pharmacies near you to find which ones can fill your prescription — and texts you the results.
Zoryve is not a controlled substance and has no DEA scheduling restrictions. Any licensed healthcare provider with prescribing authority can write a prescription for Zoryve. In practice, it is most commonly prescribed by dermatology specialists, though PCPs, NPs, and PAs can also prescribe it. Insurance prior authorization may require documentation from or consultation with a dermatologist.
Dermatologists — primary prescribers; most experienced with the full range of Zoryve formulations and indications
Primary care physicians (PCPs) — can prescribe Zoryve for mild-to-moderate cases; PA may require specialist documentation
Nurse practitioners (NPs) and physician assistants (PAs) — can prescribe Zoryve in most states, including those working in dermatology practices
Pediatricians — for pediatric patients with atopic dermatitis or psoriasis, age-appropriate formulations are available from age 2
Telehealth dermatology services can prescribe Zoryve in most states after a video or photo-based consultation. This is a convenient option for patients with limited access to in-person dermatology appointments. Services such as Teladoc Health, Apostrophe, and DermTech offer dermatology telehealth consultations.
No. Zoryve (roflumilast) is not a federally controlled substance and has no DEA scheduling. It can be prescribed by any licensed healthcare provider — including dermatologists, primary care physicians, nurse practitioners, and physician assistants — without special DEA authorization.
Prescriptions for Zoryve can be called in, faxed, or sent electronically to any pharmacy without the restrictions that apply to controlled substances (such as Schedule II drugs). Refills are also permitted. There are no quantity limits or special monitoring requirements related to controlled substance status.
For Zoryve cream 0.3% (plaque psoriasis), the most common adverse reactions reported in ≥1% of patients in clinical trials were:
Diarrhea (3.1%)
Headache (2.4%)
Insomnia (1.4%)
Nausea (1.2%)
Application site pain (1.0%)
Upper respiratory tract infection (1.0%)
Urinary tract infection (1.0%)
Zoryve is not known to cause serious side effects based on clinical trial data. However, patients should be aware of:
Severe allergic reaction: Hives, swelling, difficulty breathing — seek emergency care immediately.
Flammability risk (foam only): Zoryve foam is flammable — avoid fire, flame, and smoking during and immediately after application.
Contraindicated in liver disease: Do not use Zoryve if you have moderate to severe liver impairment (Child-Pugh B or C).
Know what you need? Skip the search.
Vtama (tapinarof)
Once-daily AhR agonist cream for plaque psoriasis (adults) and atopic dermatitis (age 2+). Steroid-free. Similar once-daily use, different mechanism than Zoryve.
Opzelura (ruxolitinib)
Topical JAK inhibitor cream for mild to moderate atopic dermatitis (age 12+) and vitiligo. Steroid-free; carries a boxed warning for serious infections and malignancies.
Eucrisa (crisaborole)
Topical PDE4 inhibitor ointment for atopic dermatitis (age 3 months+). Works by same mechanism as Zoryve; older generation with slightly lower efficacy in direct comparisons.
Otezla (apremilast)
Oral PDE4 inhibitor for plaque psoriasis and psoriatic arthritis. Same drug class as Zoryve but taken by mouth for more widespread disease.
Prefer Zoryve? We can find it.
CYP3A4 inhibitors (erythromycin, ketoconazole, itraconazole)
moderateMay increase roflumilast systemic exposure by inhibiting its metabolic clearance. Weigh potential for increased adverse reactions against benefit if co-administered.
Dual CYP3A4/CYP1A2 inhibitors (fluvoxamine, enoxacin, cimetidine)
moderateDual inhibition of both metabolic pathways can significantly increase roflumilast blood levels. Greater caution warranted compared to single CYP inhibitors.
Oral contraceptives with gestodene and ethinyl estradiol
minorMay increase roflumilast systemic exposure. Note: gestodene-containing contraceptives are not currently available in the US, limiting practical relevance for US patients.
Zoryve represents a meaningful advance in topical dermatology — a steroid-free PDE4 inhibitor with proven efficacy across three common inflammatory skin conditions, a favorable safety profile, and the ability to be used long-term on any body site. The AAD's 2025 guidelines endorsement of Zoryve cream 0.15% for atopic dermatitis further validates its place in modern treatment algorithms.
The main barriers to access are cost and insurance hurdles, not supply. The ZORYVE Direct Savings Card and Arcutis Cares Patient Assistance Program can dramatically reduce or eliminate out-of-pocket costs for most eligible patients.
If you've been prescribed Zoryve and are having trouble finding it at a pharmacy near you, medfinder can help. We call pharmacies near your location to find which ones can fill your prescription, and text you the results — so you can get back to focusing on your health, not the pharmacy runaround.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
Real-time availability
Medfinder is actively checking pharmacy inventory for Zoryve. We don't publish a number until we have enough verified pharmacy checks to be accurate — start a search and our team confirms current availability near you, usually within 24 hours.
ChatGPT
Claude
Gemini